Medical Patent News

RSS

Mallinckrodt, Actavis enter settlement agreement to resolve Exalgo patent litigation

Actavis, Inc. today announced that it has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo (Hydromorphone Hydrochloride Extended-Release) tablets.

15 Feb 2013

Sucampo, R-Tech Ueno and Takeda file patent infringement lawsuit against Anchen for AMITIZA

Sucampo Pharmaceuticals, Inc. announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited and certain affiliates of Takeda, has filed a patent infringement lawsuit against Anchen Pharmaceuticals, Inc., which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of AMITIZA (lubiprostone) oral capsules, and certain affiliates of Anchen.

12 Feb 2013

USPTO issues patent to KAHR-101 for treatment of cancers, arthritis and MS

Hadasit Bio-Holdings Ltd., a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, KAHR Medical Ltd., was granted a U.S. patent approval (U.S. Patent No. 8329657).

5 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

RBC Life Sciences receives U.S. patent for Neurobright supplement

RBC Life Sciences, Inc., has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering. The Company markets this supplement under the name "Neurobright."

31 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

High blood calcium levels may predict ovarian cancer

A new study from Wake Forest Baptist Medical Center is the first to report that high blood calcium levels might predict of ovarian cancer, the most fatal of the gynecologic cancers.

25 Jan 2013

Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.

23 Jan 2013

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

IntelliCell BioSciences, Inc. announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells."

23 Jan 2013

Catheter Connections receives U.S. patent for DualCap IV disinfection technology

Catheter Connections, a start-up company co-founded by nurses seeking to reduce deadly hospital-acquired bloodstream infections, announced today the issuance of U.S. Patent Number 8,343,112.

18 Jan 2013

Thermo Scientific, UT Arlington receive U.S. patent for Dionex QD detector

The University of Texas at Arlington and Thermo Fisher Scientific Inc., the world leader in serving science, announced that they have been granted a United States patent (#8,293,099) for a novel charge detector for ion chromatography that they developed together.

From Thermo Fisher Scientific Inc. 20 Dec 2012

USPTO approves patent for Axiogenesis’ in vitro drug discovery assay to treat HCM

The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM).

5 Dec 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

Forest, Alkem and Torrent settle generic BYSTOLIC patent infringement litigation

Forest Laboratories, Inc. and Forest Laboratories Holdings, Ltd. announced today that they have entered into settlement agreements with Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., and Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. in patent infringement litigation brought by Forest in response to abbreviated new drug applications (ANDAs) filed by Alkem, Indchemie and Torrent each seeking approval to market generic versions of Forest's BYSTOLIC (nebivolol) tablets.

29 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate.

26 Nov 2012

Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Medgenics, Inc., the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO).

22 Nov 2012

Rexahn's quinoxalinyl-piperazine compounds receive U.S. patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."

21 Nov 2012

Texas Biomed applies patent for new genetically-engineered vaccine strategy to prevent HIV

The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus.

20 Nov 2012

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.